Alumis reported positive topline results from two Phase 3 trials (Onward1 and Onward2) of envudeucitinib, a selective oral TYK2 inhibitor, meeting primary and key secondary endpoints in moderate‑to‑severe plaque psoriasis. The trials showed strong skin‑clearance rates at week 16 with consistent results across both studies. Alumis said it will pursue regulatory filings this year. The success accelerates competition in the oral TYK2 class and could position envudeucitinib as an alternative to existing therapies if full data confirm efficacy and safety. Investors reflected the development in a significant share price move following the announcement.